source
- AstraZeneca and Amgen’s Tezspire eyes Dupixent’s EoE stronghold after late-stage trial winAnalysts note that AstraZeneca and Amgen have secured a late‑stage trial win for Tezspire, positioning the drug as a possible challenger to Dupixent in eosinophilic esophagitis (EoE). Dupixent re…
- Cytokinetics reports positive pivotal trial results for aficamten in non-obstructive hypertrophic cardiomyopathyBiotech Cytokinetics disclosed full data from a pivotal study of its drug aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The trial met both primary endpoints, showin…